Loading company
AgomAb Therapeutics NV
AGMB · Nasdaq · ·
$10.46+2.0%Sep 29 close
- 1M
- -20.6%
- 6M
- +6.1%
AGMB · Nasdaq · ·
$10.46+2.0%Sep 29 close
From the company’s own 6-K filing.
“In the first half of 2026, we continued to execute on our clinical and operational strategy, and we are on track with the clinical read-outs and trial initiations of ontunisertib and AGMB-447 expected later this year,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Crohn’s Disease Crohn’s disease is a chronic progressive disease of the gastrointestinal tract. It is estimated that approximately 46% of patients with Crohn’s disease have fibrosis of the gastrointestinal tract, resulting in stricture formation and intestinal obstructions, most frequently in the terminal ileum. These strictures can cause obstructive symptoms leading to dietary change, malnutrition and surgery. Despite the large unmet medical need, there are no approved pharmacological therapies for FSCD.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K AgomAb Therapeutics NV filed on August 6, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
AgomAb Therapeutics NV has no earnings call transcript available.